JP2012509348A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509348A5
JP2012509348A5 JP2011537624A JP2011537624A JP2012509348A5 JP 2012509348 A5 JP2012509348 A5 JP 2012509348A5 JP 2011537624 A JP2011537624 A JP 2011537624A JP 2011537624 A JP2011537624 A JP 2011537624A JP 2012509348 A5 JP2012509348 A5 JP 2012509348A5
Authority
JP
Japan
Prior art keywords
disease
pharmaceutically acceptable
acceptable salt
composition
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011537624A
Other languages
English (en)
Japanese (ja)
Other versions
JP5535233B2 (ja
JP2012509348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/065188 external-priority patent/WO2010059853A1/en
Publication of JP2012509348A publication Critical patent/JP2012509348A/ja
Publication of JP2012509348A5 publication Critical patent/JP2012509348A5/ja
Application granted granted Critical
Publication of JP5535233B2 publication Critical patent/JP5535233B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011537624A 2008-11-19 2009-11-19 Ｔｇｒ５モジュレーターおよびその使用方法 Expired - Fee Related JP5535233B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08169462.2 2008-11-19
EP08169462 2008-11-19
PCT/US2009/065188 WO2010059853A1 (en) 2008-11-19 2009-11-19 Tgr5 modulators and method of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014088019A Division JP2014159456A (ja) 2008-11-19 2014-04-22 Ｔｇｒ５モジュレーターおよびその使用方法

Publications (3)

Publication Number Publication Date
JP2012509348A JP2012509348A (ja) 2012-04-19
JP2012509348A5 true JP2012509348A5 (https=) 2012-12-13
JP5535233B2 JP5535233B2 (ja) 2014-07-02

Family

ID=41668454

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011537624A Expired - Fee Related JP5535233B2 (ja) 2008-11-19 2009-11-19 Ｔｇｒ５モジュレーターおよびその使用方法
JP2014088019A Withdrawn JP2014159456A (ja) 2008-11-19 2014-04-22 Ｔｇｒ５モジュレーターおよびその使用方法
JP2015160141A Pending JP2015232020A (ja) 2008-11-19 2015-08-14 Ｔｇｒ５モジュレーターおよびその使用方法
JP2017083045A Withdrawn JP2017132803A (ja) 2008-11-19 2017-04-19 Ｔｇｒ５モジュレーターおよびその使用方法
JP2018059922A Withdrawn JP2018100304A (ja) 2008-11-19 2018-03-27 Ｔｇｒ５モジュレーターおよびその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014088019A Withdrawn JP2014159456A (ja) 2008-11-19 2014-04-22 Ｔｇｒ５モジュレーターおよびその使用方法
JP2015160141A Pending JP2015232020A (ja) 2008-11-19 2015-08-14 Ｔｇｒ５モジュレーターおよびその使用方法
JP2017083045A Withdrawn JP2017132803A (ja) 2008-11-19 2017-04-19 Ｔｇｒ５モジュレーターおよびその使用方法
JP2018059922A Withdrawn JP2018100304A (ja) 2008-11-19 2018-03-27 Ｔｇｒ５モジュレーターおよびその使用方法

Country Status (23)

Country Link
US (5) US8114862B2 (https=)
EP (2) EP2698375B1 (https=)
JP (5) JP5535233B2 (https=)
KR (2) KR101789960B1 (https=)
CN (2) CN104370990A (https=)
AU (1) AU2009316566B9 (https=)
BR (1) BRPI0921983B8 (https=)
CA (1) CA2744189C (https=)
DK (2) DK2698375T3 (https=)
EA (2) EA020140B1 (https=)
ES (2) ES2663948T3 (https=)
HK (1) HK1205132A1 (https=)
HU (1) HUE039171T2 (https=)
IL (3) IL212969A (https=)
LT (1) LT2698375T (https=)
MX (1) MX2011005295A (https=)
NO (1) NO2698375T3 (https=)
PL (2) PL2376519T3 (https=)
PT (2) PT2698375T (https=)
SG (1) SG10201400162QA (https=)
SI (1) SI2698375T1 (https=)
WO (1) WO2010059853A1 (https=)
ZA (1) ZA201104077B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2248581T3 (es) 2001-03-12 2006-03-16 Intercept Pharmaceuticals, Inc. Esteroides como agonistas de fxr.
PL1734970T3 (pl) 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
KR101555716B1 (ko) 2007-01-19 2015-09-25 인터셉트 파마슈티컬즈, 인크. Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법
WO2010014836A2 (en) 2008-07-30 2010-02-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
DK2698375T3 (en) * 2008-11-19 2018-05-28 Intercept Pharmaceuticals Inc TGR5 modulators and methods for using them
CA2744817C (en) 2008-11-26 2020-07-07 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
JP2012509892A (ja) 2008-11-26 2012-04-26 サティオゲン ファーマシューティカルズ，インク． サティオゲン類を含有する組成物及び使用の方法
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CA2852957C (en) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
SI3336097T1 (sl) 2012-06-19 2021-07-30 Intercept Pharmaceuticals, Inc. Priprava nekristalinične oblike obetiholne kisline
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
WO2014059008A1 (en) 2012-10-09 2014-04-17 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
WO2014059009A1 (en) 2012-10-09 2014-04-17 The Procter & Gamble Company Method of identifying synergistic cosmetic combinations
US9884066B2 (en) 2013-06-06 2018-02-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Bile acid-basic amino acid conjugates and uses thereof
WO2014200349A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceutical B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
CA3236835A1 (en) 2013-11-22 2015-05-28 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
SMT202000070T1 (it) * 2014-05-29 2020-03-13 Bar Pharmaceuticals S R L Derivati del colano per l'uso del trattamento e/o la prevenzione di malattie mediate da fxr e tgr5/gpbar1
WO2016054208A1 (en) * 2014-10-03 2016-04-07 Mayo Foundation For Medical Education And Research Targeting tgr5 to treat disease
SG11201703717SA (en) * 2014-11-06 2017-06-29 Enanta Pharm Inc Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
KR102546748B1 (ko) 2014-11-19 2023-06-22 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
KR102527821B1 (ko) 2014-11-19 2023-05-02 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
EA033445B1 (ru) 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
CN107207559B (zh) 2014-11-19 2019-10-25 Nzp英国有限公司 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
JP2018519246A (ja) * 2015-04-28 2018-07-19 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド コール酸誘導体、及びその製造方法及び医薬用途
US10800807B2 (en) 2015-06-19 2020-10-13 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
JP6861703B2 (ja) * 2015-06-19 2021-04-21 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｔｇｒ５修飾物質およびその使用方法
AU2016325619A1 (en) * 2015-09-24 2018-04-12 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
MA42339A1 (fr) * 2015-10-07 2019-01-31 Intercept Pharmaceuticals Inc Modulateurs du récepteur farnésoïde x
CN106008639B (zh) * 2016-03-11 2019-01-08 深圳市塔吉瑞生物医药有限公司 用于预防或治疗fxr-介导疾病的胆烷酸化合物
WO2017180577A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
WO2017210147A1 (en) 2016-05-29 2017-12-07 Wei Jia Liver disease-related biomarkers and methods of use thereof
US10654834B2 (en) * 2016-07-01 2020-05-19 Venenum Biodesign, LLC Non-systemic TGR5 agonists
WO2018222701A1 (en) * 2017-05-30 2018-12-06 Intercept Pharmaceuticals, Inc. Treatment of renal diseases with a bile acid derivative
CN109021056B (zh) * 2017-06-09 2021-03-09 博瑞生物医药（苏州）股份有限公司 法尼酯x受体激动剂
CA3070837A1 (en) 2017-07-24 2019-01-31 Intercept Pharmaceuticals, Inc. Isotopically labeled bile acid derivatives
CA3075205A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2020163201A1 (en) * 2019-02-04 2020-08-13 Intercept Pharmaceuticals, Inc. Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative
CN116925168A (zh) 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
KR102693566B1 (ko) * 2020-07-03 2024-08-08 주식회사 큐라클 지방간 질환의 예방 또는 치료를 위한 약학적 조성물
CN113774142A (zh) * 2021-10-11 2021-12-10 北京化工大学 Tgr5在制备治疗肠癌药物及诊断性试剂盒中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3366932D1 (en) 1982-07-29 1986-11-20 Lehner Ag New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
IT1206112B (it) 1983-04-29 1989-04-14 Lehner Ag Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1212835B (it) 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
US4892868A (en) 1984-08-17 1990-01-09 Gipharmex, S.P.A. Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
IT1196377B (it) 1984-12-21 1988-11-16 Lehner Ag Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche
IT1223313B (it) 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
US5175320A (en) 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
IT1229570B (it) 1989-04-17 1991-09-04 Giuliani Spa Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
ES2074113T3 (es) 1989-12-13 1995-09-01 Mitsubishi Chem Corp Nuevos derivados de acido pirazolil acrilico, utiles como fungicidas sistemicos para la proteccion de plantas y materiales.
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5689791A (en) 1996-07-01 1997-11-18 Xerox Corporation Electrically conductive fibers
EP0921798A1 (en) 1996-07-12 1999-06-16 Smithkline Beecham Plc Novel treatment of leptine resistance
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
CA2318731C (en) 1998-01-29 2012-05-29 Tularik Inc. Ppar-gamma modulators
WO2000025134A1 (en) 1998-10-23 2000-05-04 Glaxo Group Limited Assays for ligands for nuclear receptors
DE69940958D1 (de) 1998-12-23 2009-07-16 Glaxo Group Ltd Bestimmungsmethode fur liganden der nuklearen rezeptoren
WO2000040965A1 (en) 1999-01-07 2000-07-13 Tularik, Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
EP1473042B1 (en) 1999-03-26 2006-06-21 City of Hope Screening for FXR receptor modulators
AU780658B2 (en) 1999-03-26 2005-04-07 City Of Hope Method of affecting cholesterol catabolism using nuclear bile acid receptor
CN1368884A (zh) 1999-06-11 2002-09-11 阿勒根销售公司 用于调节fxr受体活性的方法
US6906057B1 (en) 1999-06-11 2005-06-14 Allergan, Inc. Methods for modulating FXR receptor activity
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
CA2386750A1 (en) 1999-10-22 2001-05-03 Merck & Co. Inc. Pharmaceuticals for treating obesity
WO2001077325A1 (fr) 2000-04-12 2001-10-18 Takeda Chemical Industries, Ltd. Nouvelle proteine de recepteur couple aux proteines g et adn de celle-ci
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
US20020119958A1 (en) 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
ES2248581T3 (es) 2001-03-12 2006-03-16 Intercept Pharmaceuticals, Inc. Esteroides como agonistas de fxr.
US7354726B2 (en) 2001-04-12 2008-04-08 Takeda Pharmaceutical Company Limited Screening method
US20070010562A1 (en) 2001-08-13 2007-01-11 Ulrike Bauer Nr1h4 nuclear receptor binding compounds
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
WO2003015777A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
US20030144360A1 (en) 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
US20050107475A1 (en) 2002-03-21 2005-05-19 Jones Stacey A. Methods of using farnesoid x receptor (frx) agonists
AU2003228485A1 (en) 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
JPWO2004000752A1 (ja) 2002-06-19 2005-10-20 株式会社アベイラス 人造石壁材
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
WO2004048349A1 (en) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
US7625887B2 (en) 2003-01-28 2009-12-01 Takeda Pharmaceutical Company Limited Receptor agonists
WO2005032549A1 (en) 2003-09-26 2005-04-14 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
PL1734970T3 (pl) 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US7932244B2 (en) 2006-06-27 2011-04-26 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
EP1947108A1 (en) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
KR101555716B1 (ko) * 2007-01-19 2015-09-25 인터셉트 파마슈티컬즈, 인크. Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법
DK2698375T3 (en) * 2008-11-19 2018-05-28 Intercept Pharmaceuticals Inc TGR5 modulators and methods for using them

Similar Documents

Publication Publication Date Title
JP2012509348A5 (https=)
JP2012514009A5 (https=)
JP2018518537A5 (https=)
JP2009502793A5 (https=)
JP2009545527A5 (https=)
Pirollo et al. Antisense therapeutics: from theory to clinical practice
JP2013507439A5 (https=)
JP2012512907A5 (https=)
JP2010521516A5 (https=)
JP2009502743A5 (https=)
JP2014515013A5 (https=)
JP2006515626A5 (https=)
JP2010515715A5 (https=)
JP2012532874A5 (https=)
JP2011520965A5 (https=)
JP2015145410A5 (https=)
JP2011526886A5 (https=)
JP2011527332A5 (https=)
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
JP2014511863A5 (https=)
JP2009543799A5 (https=)
JP2008533007A5 (https=)
JP2011528658A5 (https=)
JP2007302689A5 (https=)
JP2011505356A5 (https=)